Definitions
from The American Heritage® Dictionary of the English Language, 5th Edition.
- noun A humanized monoclonal antibody used intravenously to treat metastatic breast cancer.
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A drug used in the treatment of
breast cancer which targets theHER-2 oncogene.
Etymologies
from The American Heritage® Dictionary of the English Language, 4th Edition
Support
Help support Wordnik (and make this page ad-free) by adopting the word trastuzumab.
Examples
-
Specifically, we show that responsiveness to alternative HER-targeted inhibitors, such as gefitinib and cetuximab, is dramatically potentiated by long-term trastuzumab treatment of ovarian cancer cells.
BioMed Central - Latest articles Jason Wilken 2010
-
The drug, known as trastuzumab-DM1, or T-DM1, is the first conjugated monoclonal antibody to be reviewed by the FDA and has realistic chances to be approved in some breast cancer patients by the regulator given the medicine's strong trial results, analysts said.
-
Treatment with a drug called trastuzumab Herceptin can block the growth signals transmitted by the gene, slowing the progress of the cancer and making it more susceptible to chemotherapy, Russell said.
-
Roche is using Halozyme's human hyaluronidase to develop an injectible form of trastuzumab, which is currently available only as an intravenous drug that takes about an hour to administer, often in a hospital.
Fore, right! 2010
-
The use of intact antibodies as the basis for radiotracer development, such as trastuzumab which is used routinely in the clinic worldwide, also has the advantage of expediting preclinical and clinical translation.
PLoS ONE Alerts: New Articles Jason P. Holland et al. 2010
-
Genentech unit has filed an application with the Food and Drug Administration for a novel cancer drug, known as trastuzumab-DM1, the company said Wednesday.
Los Angeles Business News - Local Los Angeles News | Los Angeles Business from bizjournals 2010
-
The drug, called trastuzumab-DM1, or T-DM1 for short, is designed to help women with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies, including Genentech's Herceptin.
-
Roche is using Halozyme's human hyaluronidase to develop an injectible form of trastuzumab, which is currently available only as an intravenous drug that takes about an hour to administer, often in a hospital.
Fore, right! 2010
-
T-DM1 is composed of the breast cancer drug trastuzumab, which is marketed as Herceptin by
-
The use of intact antibodies as the basis for radiotracer development, such as trastuzumab which is used routinely in the clinic worldwide, also has the advantage of expediting preclinical and clinical translation.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.